other material
confidence high
sentiment positive
materiality 0.85
VK2735 Phase 2 meets endpoints: up to 14.7% weight loss, 88% achieve ≥10% loss
Viking Therapeutics, Inc.
- Primary and all secondary endpoints met; up to 14.7% mean weight loss from baseline (13.1% placebo-adjusted) after 13 weeks.
- Up to 88% of VK2735-treated patients achieved ≥10% weight loss vs 4% for placebo.
- No weight loss plateau observed; reductions progressive through week 13.
- Well-tolerated: 92% of drug-related TEAEs mild/moderate; low discontinuation (13% vs 14% placebo).
- Company plans FDA meeting to discuss next steps; oral formulation data expected this quarter.